Pancreatic Cancer Research

ResearcherAzienda Ospedaliero-Universitaria CareggiNo recent work listed

Amedeo Amedei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6797-9343; OpenAlex author ID A5082342925. Sources: OpenAlex.

Their work

Papers
6 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 6

  1. Impact of microbiota-immunity axis in pancreatic cancer management. Last author DOI 10.3748/wjg.v28.i32.4527↗
  2. Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Last author DOI 10.1042/cs20150437↗
  3. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. Last author DOI 10.3892/ijo.2016.3524↗
  4. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Co-author DOI 10.4161/hv.34392↗
  5. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell … Co-author DOI 10.1007/s00262-013-1429-3↗
  6. What is recent in pancreatic cancer immunotherapy? Last author DOI 10.1155/2013/492372↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Domenico Prisco · 5 shared papers, 2013–2016 · strength 0.25
  2. Elena Niccolai · 5 shared papers, 2013–2016 · strength 0.25
  3. Mario Milco D’Elios · 4 shared papers, 2013–2016 · strength 0.18
  4. Ilenia Bartolini · 1 shared paper, 2022 · strength 0.16
  5. Lapo Bencini · 3 shared papers, 2013–2016 · strength 0.13
  6. Francesco Novelli · 3 shared papers, 2013–2016 · strength 0.13
  7. Paola Cappello · 2 shared papers, 2013–2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.